PLoS ONE (Jan 2019)

"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.

  • Pierre Gantner,
  • Babacar Sylla,
  • Laurence Morand-Joubert,
  • Pierre Frange,
  • Karine Lacombe,
  • Marie-Aude Khuong,
  • Claudine Duvivier,
  • Odile Launay,
  • Marina Karmochkine,
  • Cédric Arvieux,
  • Amélie Ménard,
  • Lionel Piroth,
  • Ana Canestri,
  • Dominique Trias,
  • Gilles Peytavin,
  • Roland Landman,
  • Jade Ghosn,
  • Coferal-IMEA048 Study Group

DOI
https://doi.org/10.1371/journal.pone.0216010
Journal volume & issue
Vol. 14, no. 4
p. e0216010

Abstract

Read online

IntroductionLimited "real life" data on raltegravir (RAL) use during pregnancy are available. Thus, we aimed at describing effectiveness and safety of RAL-based combined antiretroviral therapy (cART) in this setting.MethodsHIV-1-infected women receiving RAL during pregnancy between 2008 and 2014 in ten French centers were retrospectively analysed for: (1) proportion of women receiving RAL anytime during pregnancy who achieved a plasma HIV-RNA (pVL) ResultsWe included 94 women (median age, 33 years) of which 85% originated from Sub-Saharan Africa and 16% did not have regular health insurance coverage. Sixteen women were cART-naïve (median HIV diagnosis at 30 weeks of gestation), whereas 78 were already on cART before pregnancy (40% with pVL ConclusionsRAL appears safe and effective in this "real-life" study. No defect and no HIV transmission was reported in new-borns.